FDA approved Lumvoa for both active and chronic thyroid eye disease, supported by robust phase 3 data showing rapid and durable symptom reduction. Immediate launch is planned, with comprehensive patient support and safety monitoring guidelines in place.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.